Medincell Financials
| MEDCL Stock | EUR 17.10 0.32 1.91% |
Medincell |
Medincell Stock Summary
Medincell competes with Gensight Biologics, OSE Pharma, Eurobio Scientific, Abivax SA, and Biosynex. It develops solutions based on BEPO, a technology for long-acting injectable products based on proprietary copolymers and a biocompatible solvent, which solubilizes or suspends the active pharmaceutical ingredients. Its product candidates in formulation research comprise subcutaneous injections, such as mdc-WWM for contraception mdc-ANG for CNS related treatments mdc-ELK for depression and mdc-GRT for use in organ transplant, as well as perineural injections, including mdc-CMV for anesthesia and pain, and mdc-NVA for pain. MEDINCELL is traded on Paris Stock Exchange in France.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0004065605 |
| Business Address | 3 rue des |
| Sector | Healthcare |
| Industry | Biotechnology |
| Benchmark | Dow Jones Industrial |
| Website | www.medincell.com |
| Phone | 33 4 67 02 13 67 |
| Currency | EUR - Euro |
You should never invest in Medincell without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Medincell Stock, because this is throwing your money away. Analyzing the key information contained in Medincell's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Medincell Key Financial Ratios
Medincell's financial ratios allow both analysts and investors to convert raw data from Medincell's financial statements into concise, actionable information that can be used to evaluate the performance of Medincell over time and compare it to other companies across industries.Medincell Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Medincell's current stock value. Our valuation model uses many indicators to compare Medincell value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Medincell competition to find correlations between indicators driving Medincell's intrinsic value. More Info.Medincell SA is considered to be number one stock in return on asset category among its peers. It also is considered to be number one stock in operating margin category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Medincell's earnings, one of the primary drivers of an investment's value.Medincell SA Systematic Risk
Medincell's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Medincell volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Medincell SA correlated with the market. If Beta is less than 0 Medincell generally moves in the opposite direction as compared to the market. If Medincell Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Medincell SA is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Medincell is generally in the same direction as the market. If Beta > 1 Medincell moves generally in the same direction as, but more than the movement of the benchmark.
Medincell December 11, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Medincell help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Medincell SA. We use our internally-developed statistical techniques to arrive at the intrinsic value of Medincell SA based on widely used predictive technical indicators. In general, we focus on analyzing Medincell Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Medincell's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.59 | |||
| Information Ratio | (0.01) | |||
| Maximum Drawdown | 17.45 | |||
| Value At Risk | (3.35) | |||
| Potential Upside | 2.56 |
Additional Tools for Medincell Stock Analysis
When running Medincell's price analysis, check to measure Medincell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medincell is operating at the current time. Most of Medincell's value examination focuses on studying past and present price action to predict the probability of Medincell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medincell's price. Additionally, you may evaluate how the addition of Medincell to your portfolios can decrease your overall portfolio volatility.